Presenting on behalf of a large international team, Martin Heidinger (DBM Hebelstrasse, Basel, Switzerland), showed results from a preplanned analysis of the TAXIS/OPBC-03 phase 3 trial. Axillary lymph node dissection (ALND) is the standard of care for patients with node-positive breast cancer after neoadjuvant chemotherapy or upfront surgery. The use of tailored axillary surgery (TAS) to reduce axillary tumour burden to a degree where radiotherapy might be able to control the remaining extent of disease could reduce morbidity.
The Lancet Oncology published a clinical update in Oncology on 12 Mar 2026.
The item focuses on 2026 Society of Surgical Oncology Annual Meeting.
Review the original article for the full source wording and details.